Does a rise in theBCR-ABL1transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?-Reference-Cited by-同舟云学术

Does a rise in theBCR-ABL1transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

Published:2009-05 Issue:3 Volume:145 Page:373-375
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Marin David,Khorashad Jamshid S.,Foroni Letizia,Milojkovic Dragana,Szydlo Richard,Reid Alistair G.,Rezvani Katayoun,Bua Marco,Goldman John M.,Apperley Jane F.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07646.x/fullpdf

Reference8 articles.

1. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet;Baccarani;Blood,2006

2. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation;Cross;Blood,1993

3. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival;Druker;New England Journal of Medicine,2006

4. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy;Kaeda;Blood,2006

5. The finding of kinase domain mutations in chronic phase CML patients responding to imatinib may identify those at high risk of disease progression;Khorashad;Journal of Clinical Oncology,2008

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

2. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2020-10

3. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2018-09

4. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis;Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia;2016

5. Is cure of chronic myeloid leukemia in the third millennium a down to earth target (ed) or a castle in the air?;Cancer Letters;2014-09